There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (2)

Short Titles

Short Titles - House of Representatives

Short Titles as Introduced

Drug-Price Transparency in Communications Act

Official Titles

Official Titles - House of Representatives

Official Title as Introduced

To require drug manufacturers to disclose the prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug.


Actions Overview (1)

Date Actions Overview
07/26/2018Introduced in House

All Actions (3)

Date All Actions
07/27/2018Referred to the Subcommittee on Health.
Action By: Committee on Energy and Commerce
07/26/2018Referred to the House Committee on Energy and Commerce.
Action By: House of Representatives
07/26/2018Introduced in House
Action By: House of Representatives

Cosponsors (0)

No cosponsors.


Committees (1)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Reports
House Energy and Commerce07/26/2018 Referred to
House Energy and Commerce Subcommittee on Health07/27/2018 Referred to

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.


Subjects (4)


Latest Summary (1)

There is one summary for H.R.6576. View summaries

Shown Here:
Introduced in House (07/26/2018)

Drug-Price Transparency in Communications Act

This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.

The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.